These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35715985)

  • 1. Risks of femoral localized periosteal thickening in patients with autoimmune inflammatory rheumatic diseases.
    Sato H; Kondo N; Takai C; Kurosawa Y; Hasegawa E; Wakamatsu A; Kobayashi D; Nakatsue T; Abe A; Kazama JJ; Kuroda T; Ito S; Ishikawa H; Endo N; Narita I
    Mod Rheumatol; 2023 Jul; 33(4):803-810. PubMed ID: 35715985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis.
    Sato H; Takai C; Kondo N; Kurosawa Y; Hasegawa E; Wakamatsu A; Kobayashi D; Nakatsue T; Abe A; Ito S; Ishikawa H; Kazama JJ; Kuroda T; Suzuki Y; Endo N; Narita I
    Osteoporos Int; 2021 Feb; 32(2):363-375. PubMed ID: 32885317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and clinical course of femoral localized periosteal thickening and atypical femoral fracture over a 10-year period in patients with autoimmune inflammatory rheumatic disease.
    Sato H; Kondo N; Kurosawa Y; Hasegawa E; Wakamatsu A; Nozawa Y; Kobayashi D; Nakatsue T; Wada Y; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
    JBMR Plus; 2024 Sep; 8(9):ziae090. PubMed ID: 39119540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower trabecular bone score is associated with an increased incidence of localized femoral periosteal thickening.
    Sato H; Kondo N; Kurosawa Y; Hasegawa E; Wakamatsu A; Kobayashi D; Nakatsue T; Kazama JJ; Kuroda T; Suzuki Y; Endo N; Narita I
    J Bone Miner Metab; 2021 Nov; 39(6):952-961. PubMed ID: 34283281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
    Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
    Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH
    Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
    Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH
    Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.
    Meinen R; Galli-Lysak I; Villiger PM; Aeberli D
    BMC Musculoskelet Disord; 2016 Aug; 17():324. PubMed ID: 27491286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of bisphosphonate and non-bisphosphonate related atypical femoral fracture in a South East Asian population - Secondary analysis.
    Gani LU; Anthony NF; Dacay LM; Tan PT; Chong LR; King TFJ
    Bone; 2022 Sep; 162():116455. PubMed ID: 35688361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
    Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study.
    Lim SJ; Yeo I; Yoon PW; Yoo JJ; Rhyu KH; Han SB; Lee WS; Song JH; Min BW; Park YS
    Osteoporos Int; 2018 Nov; 29(11):2427-2435. PubMed ID: 30039251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
    Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
    J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Incidence of Atypical Femoral Fractures in Patients with Rheumatic Disease: Yamagata Prefectural Committee of Atypical Femoral Fractures (YamaCAFe) Study.
    Takakubo Y; Ohta D; Ishi M; Ito J; Oki H; Naganuma Y; Uno T; Sasaki A; Akabane T; Dairaku K; Goto S; Goto Y; Kanauchi Y; Kobayashi S; Nakajima T; Masuda K; Matsuda M; Mura N; Takenouchi K; Tsuchida H; Onuma Y; Shibuya J; Seino M; Yamaguchi O; Hiragami K; Urayama Y; Furukawa T; Okuda S; Ogura K; Nakamura T; Sasaki K; Konta T; Takagi M
    Tohoku J Exp Med; 2017 Aug; 242(4):327-334. PubMed ID: 28883214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
    Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
    BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
    Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
    Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population.
    Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS
    Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
    Katayama K; Matsuno T
    Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years.
    Lo JC; Neugebauer RS; Ettinger B; Chandra M; Hui RL; Ott SM; Grimsrud CD; Izano MA
    BMC Musculoskelet Disord; 2020 Dec; 21(1):801. PubMed ID: 33272248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
    Miyakoshi N; Aizawa T; Sasaki S; Ando S; Maekawa S; Aonuma H; Tsuchie H; Sasaki H; Kasukawa Y; Shimada Y
    J Bone Miner Metab; 2015 Sep; 33(5):553-9. PubMed ID: 25227287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.